Advertisement

Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes

  • Michael F Oliver
    Correspondence
    Requests for reprints should be addressed to Michael F. Oliver, MD, Keepier Wharf, 12 Narrow Street, London E14 8DH, United Kingdom
    Affiliations
    Cardiovascular Research Division, University of Edinburgh, and Department of Cardiology, Royal Infirmary, Edinburgh, United Kingdom
    Search for articles by this author

      Abstract

      The mechanisms leading to ventricular fibrillation that occur during acute myocardial ischemia are ill understood. Whether primary ventricular fibrillation is due to a transient imbalance of electrolytes, an alteration of membrane permeability, electrical re-entry phenomena, or other factors, one overriding influence is the development of regional myocardial energy crises. Acute alteration in the balance of substrate supply may lead, during greatly reduced blood flow, to instability of myocardial electrical conduction with the development of re-entry circuits. An immediate response to the angor animi and initial symptoms of an acute coronary syndrome is a rapid and marked increase in catecholamine release, which leads to adipose tissue lipolysis with an acute increase in plasma free fatty acid concentrations, suppression of insulin activity, and a reduction in glucose uptake by the myocardium. The utilization of free fatty acids instead of glucose by the ischemic myocardium could precipitate regional oxygen or energy crises. Prevention therefore should focus on minimizing the catecholamine response and providing the myocardium with an optimum supply of energy substrates. Since catecholamines are inotropic, the aim should be to redress the imbalance of substrate availability by controlling adipose lipolysis with reduction of plasma free fatty acid concentrations, increasing the availability of glucose, or both. Other approaches include inhibition of acylcarnitine transport and manipulation of fatty acid intermediaries. To combat primary ventricular fibrillation, preventive treatment must be established within 6 to 10 hours of the onset of ischemia. There is already experimental and clinical evidence that antilipolytic drugs decrease the incidence of ventricular fibrillation, but their potential has not been explored extensively.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Myerburg R.J.
        • Kessler K.M.
        • Castellanos A.
        Sudden cardiac death.
        Ann Intern Med. 1993; 119: 1187-1197
        • Lawrie D.M.
        • Higgins M.R.
        • Godman M.J.
        • et al.
        Ventricular fibrillation complicating acute myocardial infarction.
        Lancet. 1968; 2: 523-528
        • Singh B.N.
        • Wellens H.J.J.
        • Hiraoka M.
        Electropharmacological control of cardiac arrhythmias.
        J Cardiovasc Electrophysiol. 1994; 5: 722-730
        • Misier A.R.R.
        • Opthof T.
        • van Hemel N.M.
        • et al.
        Dispersion of ‘refractoriness’ in noninfarcted myocardium of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction.
        Circulation. 1995; 92: 1589-1597
        • Wellens H.J.
        1967-1997.
        Eur Heart J. 1998; 19: 984-989
        • Touboul P.
        A decade of clinical trials.
        Eur Heart J. 1999; 21 (In: Camm AJ, Aliot E. Evidence base for the treatment of life-threatening arrhythmias.): 1-10
        • Ferrari R.
        • Pepi P.
        • Ferrari F.
        • et al.
        Metabolic derangement in ischemic heart disease and its therapeutic control.
        Am J Cardiol. 1998; 82: 2K-13K
        • Taegtmeyer H.
        Modulation of responses to myocardial ischemia.
        in: Dilsizian V. Myocardial Viability: A Clinical and Scientific Treatise. Futura Publishing Co., Inc, Armonk, New York2000: 25-35
        • Vetter N.J.
        • Strange R.C.
        • Adams W.
        • Oliver M.F.
        Initial metabolic and hormonal response to acute myocardial infarction.
        Lancet. 1974; 1: 284-288
        • Valori C.
        • Thomas M.
        • Shillingford J.
        Free noradrenaline and adrenaline excretion in relation to clinical syndromes following myocardial infarction.
        Am J Cardiol. 1967; 20: 605-612
        • Kurien V.A.
        • Oliver M.F.
        Serum-free-fatty-acids after acute myocardial infarction and cerebral vascular occlusion.
        Lancet. 1966; 2: 122-127
        • Opie L.H.
        Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction.
        Am J Cardiol. 1975; 36: 938-953
        • Mueller H.S.
        • Ayres S.M.
        Metabolic responses of the heart in acute myocardial infarction in man.
        Am J Cardiol. 1978; 42: 363-371
        • Neely J.R.
        • Morgan H.E.
        Relationship between carbohydrate and lipid metabolism and the energy balance of the heart.
        Ann Rev Physiol. 1974; 36: 413-459
        • Oliver M.F.
        • Boyd G.S.
        Serum lipoprotein patterns in coronary sclerosis and associated conditions.
        Br Heart J. 1955; 17: 299-305
        • Oliver M.F.
        • Kurien V.A.
        • Greenwood T.W.
        Relation between serum free fatty acids and arrhythmias and death after acute myocardial infarction.
        Lancet. 1968; 1: 710-715
        • Tansey M.J.
        • Opie L.H.
        Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction.
        Lancet. 1983; 2: 419-422
        • Jouven X.
        • Charles M.-A.
        • Desnos M.
        • Ducimetiere P.
        Circulating non-esterified fatty acid level as a predictive risk factor for sudden death in the population.
        Circulation. 2001; 104: 756-761
        • Kurien V.A.
        • Oliver M.F.
        A metabolic cause for arrhythmias during acute myocardial hypoxia.
        Lancet. 1970; 2: 813-815
        • Soloff L.A.
        Arrhythmias following infusions of fatty acids.
        Am Heart J. 1970; 80: 671-674
        • Kurien V.A.
        • Yates P.A.
        • Oliver M.F.
        Free fatty acids, heparin and arrhythmias during experimental myocardial infarction.
        Lancet. 1969; 3: 185-187
        • Strange R.C.
        • Rowe M.J.
        • Mjøs O.D.
        • Oliver M.F.
        The effect of antilipolytic agents on cyclic AMP, free fatty acid and total catecholamine concentrations in plasma.
        Acta Med Scand. 1976; 199: 421-424
        • Nimmo I.A.
        • Smith R.H.
        • Dolder M.A.
        • Oliver M.F.
        Turnover of plasma glucose and free fatty acids in patients on the first day after acute myocardial infarction.
        Clin Sci Mol Med. 1976; 50: 401-407
        • Taegtmeyer H.
        • Russell R.R.
        Essential fuels for the heart and mechanical restitution.
        in: Dilsizian V. Myocardial Viability: A Clinical and Scientific Treatise. Futura Publishing Co., Inc, Armonk, New York2000: 91-104
        • Oliver M.F.
        • Opie L.H.
        Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias.
        Lancet. 1994; 343: 155-158
        • Lopaschuk G.D.
        Optimizing cardiac energy metabolism.
        Eur Heart J. 1999; 1: O32-O39
        • Vaughan M.
        The mechanism of the lipolytic action of catecholamines.
        Ann NY Acad Sci. 1967; 139: 841-848
        • Fischbach P.S.
        • Corr P.B.
        • Yamada K.A.
        Long-chain acylcarnitine increases intracellular Ca2+ and induces afterdepolarization in adult ventricular myocytes.
        Circulation. 1992; 86: 748
        • Hendrickson S.C.
        • St Louis J.D.
        • Lowe J.E.
        • Abdel-Aleem S.
        Free fatty acid metabolism during myocardial ischemia and reperfusion.
        Mol Cell Biochem. 1997; 166: 85-94
        • Mjøs O.D.
        Effect of free fatty acids on myocardial functions and oxygen consumption in intact dogs.
        J Clin Invest. 1971; 50: 1386-1389
        • Russell D.C.
        • Lawrie J.S.
        • Riemersma R.A.
        • Oliver M.F.
        Metabolic aspects of rhythm disturbances.
        Acta Med Scand. 1981; 210: 71-80
        • Spector A.A.
        The transport and utilization of free fatty acid.
        Ann NY Acad Sci. 1968; 149: 768-778
        • Makiguchi M.
        • Kawaguchi H.
        • Tamura M.
        • Yasuda H.
        Effect of palmitic acid and fatty acid binding protein on ventricular fibrillation threshold in the perfused rat heart.
        Cardiovasc Drugs Ther. 1991; 5: 753-762
        • Miller N.E.
        • Mjos O.D.
        • Oliver M.F.
        Relationship of epicardial ST segment elevation to the plasma free fatty acid/albumin ratio during coronary occlusion in dogs.
        Clin Sci Mol Med. 1976; 51: 209-213
        • Kurien V.A.
        • Yates P.A.
        • Oliver M.F.
        The role of free fatty acids in the production of ventricular arrhythmias after acute coronary artery occlusion.
        Eur J Clin Invest. 1971; 1: 225-241
        • McLennan P.L.
        • Bridle T.M.
        • Abeywardena M.Y.
        • Charnock J.S.
        Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey.
        Am Heart J. 1992; 123: 1555-1561
        • Billman G.E.
        • Kang J.X.
        • Leaf A.S.
        Prevention of sudden cardiac death by dietary pure ω-3 polyunsaturated fatty acids in dogs.
        Circulation. 1999; 99: 2452-2457
        • Li Y.
        • Kang J.X.
        • Leaf A.
        Differential effects of various eicosanoids on the production or prevention of arrhythmias in cultured neonatal rat cardiac myocytes.
        Prostaglandins. 1997; 54: 511-530
        • Sparagna G.C.
        • Hickson-Bick D.L.
        Cardiac fatty acid metabolism and the induction of apoptosis.
        Am J Med Sci. 1999; 318: 15-21
        • Kantor P.F.
        • Dyck J.R.B.
        • Lopaschuk G.D.
        Fatty acid oxidation in the perfused ischemic heart.
        Am J Med Sci. 1999; 318: 3-14
        • Apstein C.S.
        Metabolic approaches in ischaemic heart disease.
        Eur Heart J. 1999; 1: O1-O10
        • Kendall M.J.
        • Lynch K.P.
        • Hjalmarson A.
        • Kjekshus J.
        β-blockers and sudden death.
        Ann Intern Med. 1995; 123: 358-367
        • Hjalmarson A.
        Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?.
        Basic Res Cardiol. 2000; 95: 41-45
        • Lopashuk G.D.
        • Kozak R.
        Trimetazidine inhibits fatty acid oxidation in the heart.
        J Mol Cell Cardiol. 1998; 30: A112
        • Bagger J.P.
        • Botker H.E.
        • Thomassen A.
        • Nielsen T.T.
        Effects of ranolazine on ischemic threshold, coronary sinus blood flow and myocardial metabolism in coronary artery disease.
        Cardiovasc Drugs Ther. 1997; 11: 479-484
        • Detry J.M.
        • Sellier P.
        • Pennaforte S.
        • et al.
        Trimetazidine.
        Br J Clin Pharmacol. 1994; 37: 279-288
        • Diaz R.
        • Paolasso E.C.
        • Piegas L.S.
        Metabolic modulation of acute myocardial infarction. The ECLA Glucose-Insulin-Potassium pilot trial.
        Circulation. 1998; 98: 2227-2234
        • Malmberg K.
        • DIGAMI group
        Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus.
        BMJ. 1997; 314: 1512-1515
        • Apstein C.S.
        • Opie L.H.
        Glucose-insulin-potassium (GIK) for acute myocardial infarction.
        Cardiovasc Drugs Ther. 1999; 13: 185-189
        • Vik-Mo H.
        • Riemersma R.A.
        • Mjøs O.D.
        • Oliver M.F.
        Effect of myocardial ischaemia and antilipolytic agents on lipolysis and fatty acid metabolism in the in situ dog heart.
        Scand J Clin Lab Invest. 1979; 39: 559-568
        • Rowe M.J.
        • Neilson J.M.M.
        • Oliver M.F.
        Control of ventricular arrhythmias during myocardial infarction by anti-lipolytic treatment using a nicotinic acid analogue.
        Lancet. 1975; 1: 295-302
        • Kjekshus J.K.
        • Mjøs O.D.
        Effect of inhibition of lipolysis on infarct size after experimental coronary artery occlusion.
        J Clin Invest. 1973; 52: 1770-1776
        • Russell D.C.
        • Oliver M.F.
        Effect of antilipolytic therapy on ST seg-ment elevation during myocardial ischaemia in man.
        Br Heart J. 1978; 40: 117-123
        • Luxton M.R.
        • Miller N.E.
        • Oliver M.F.
        Anti-lipolytic therapy in angina pectoris.
        Br Heart J. 1976; 38: 1204-1208
        • Olivecrona T.
        • Olivecrona G.
        Lipoprotein and hepatic lipase in lipoprotein metabolism.
        in: Betteridge D.J. Illingworth D.R. Shepherd J. Lipoproteins in Health and Disease. Arnold, London, United Kingdom1999: 223-246
        • Lopaschuk G.D.
        Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
        Am J Cardiol. 1998; 82: 14K-17K